RxDoctor Payments Data

Dawn Smedley, APRN

Clinical Nurse Specialist · Fayetteville, ARNPI 1104361864

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Abbott at 29.3% of the total.

$2,066in general payments, 2019–2025

Across 134 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$605
  • Pfizer$531
  • Amgen$243
  • Johnson & Johnson$173
  • Medtronic$98
  • E.r. Squibb & Sons, L.L.C.$90
  • plus $326 from 12 others

What the payments were for

  • Food & beverage$2,066100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical nurse specialist providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$64,964
Medicare patients
332
Services billed
660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$167,646
EntrestoSacubitril/Valsartan200$166,812
XareltoRivaroxaban155$129,235
JardianceEmpagliflozin136$104,555
BrilintaTicagrelor61$29,563
Repatha SureclickEvolocumab26$21,601
FarxigaDapagliflozin Propanediol32$17,857
Praluent PenAlirocumab11$9,297
Rosuvastatin Calcium344$4,282
Metoprolol Succinate345$3,369
Atorvastatin Calcium269$2,599
Ranolazine ErRanolazine24$2,303
Ezetimibe150$2,130
Spironolactone383$1,846
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$1,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$531$167,646194 claims
NovartisEntresto$57$166,812200 claims
Johnson & JohnsonXarelto$173$129,235155 claims
AstraZenecaBrilinta, Farxiga$62$47,42093 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical nurse specialist providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other clinical nurse specialist in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →